Scientists Retract Study That Found Hydroxychloroquine Risky For COVID-19


Two weeks after a high-profile journal The Lancet reported that the antimalarial drug hydroxychloroquine might be risky to patients with COVID-19, three of its four professionals have retracted the work because they were unable to independently verify their data set.

The controversial research, claimed that coronavirus patients who were treated with hydroxychloroquine had a higher death rate because the drug increased heart malfunctions.

The experts said their findings were based on a pool of 96,032 coronavirus patients who averaged 53-58 years across from 671 hospitals worldwide.

They also claimed to have examined 8,910 COVID-19 patients from mid-March at nearly 170 medical facilities in Asia, Europe and North America.

Scientists Retract Study That Found Hydroxychloroquine Risky For COVID-19

“Our findings suggest not only an absence of therapeutic benefit but also potential harm with the use of hydroxychloroquine or chloroquine drug regimens,” the doctors wrote, admitting that “observational studies cannot fully account for unmeasured confounding factors.”

938 New COVID-19 Infections, 8 Deaths Recorded Across 19 States, FCT

The dataset was purportedly compiled by Chigaco-based Surgisphere Corporation, which is run by Sapan Desai, a medical doctor, who was one of the four co-authors of the report. Mandeep Mehra, a professor and cardiovascular disease expert at Harvard Medical School, was one of the co-authors of the article, which also carried bylines of Frank Ruschitzka and Amit Patel, both medical doctors.

Aside from the New England Journal of Medicine and The Lancet, the research was also widely published by major media organisations across the world, with most of them citing both organisation’s long-standing credibility in the publication of scientific breakthroughs.

Previous observational studies have also expressed doubts about any apparent benefit for chloroquine use against COVID-19, the latest research sparked further concerns because it claimed the drug was more likely to lead to higher mortality.

ACPN, Pharmalliance, Others Applaud New Heights’ Ultra-Modern Cooling Facility

Days after the article earned worldwide circulation on  22 May 2020, the WHO announced on 25 May  that it was suspending clinical trials for chloroquine in the treatment of Coronavirus patients.

“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the solidarity trial, while the safety data is reviewed by the data safety monitoring board,” the WHO’s chief Tedros Ghebreyesus said in a statement.

Skeptical medical experts later raised concerns about the logical and factual basis of the research, with many saying they had never heard of Surgisphere prior to the viral claim of its associated medical experts.

Over 100 doctors, researchers and data scientists from across the world, including many from Africa and Australia, said the data that formed the basis of the published findings was not transparent and should be subjected to a third party review. Their protest was addressed to the New England Journal of Medicine and its editor, Eric Rubin.

BREAKING: PSN Postpones Omoluabi 2020 to 9-14 November

After multiple attempts to get Mr Desai to release the research’s raw data fell through, the New England Journal of Medicine and The Lancet succumbed to public outrage and skepticism over the article.

Three co-authors of the research broke with Mr Desai and retracted on Thursday, saying they “can no longer vouch for the veracity of the primary data sources.”

The WHO resumed clinical trials of hydroxychloroquine following widespread suspicion over the accuracy of the research by Mr Desai and three others.







Please enter your comment!
Please enter your name here